Skip to main content
. 2019 Aug 19;8(8):1251. doi: 10.3390/jcm8081251

Figure 2.

Figure 2

Kaplan–Meier curves for radiographic progression-free survival (rPFS), time to prostate specific antigen (PSA) progression (TTPP), and overall survival (OS) from the initiation of the first-line treatment. Note that there was no significant difference in rPFS, TTPP, and OS between abiraterone and enzalutamide from the first-line treatment.